Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
The trial reported that none of the 13 patients treated so far have experienced serious adverse events related to ENV-105.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance